U.S. Continuous Renal Replacement Therapy (CRRT) Market Outlook to 2030
By Product Type, By Modality, By End User, By Clinical Indication, By Technology Tier, and By Region
Report Overview
Report Code
TDR0362
Coverage
North America
Published
October 2025
Pages
80
On This Page
Report Overview
Executive summary will be available soon.
Report Coverage
Verified Market Sizing
Multi-layer forecasting with historical data and 5–10 year outlook
Deep-Dive Segmentation
Cross-sectional analysis by product type, end user, application and region
Competitive Benchmarking & Positioning
Market share, operating model, pricing and competition matrices
Actionable Insights & Risk Assessment
High-growth white spaces, underserved segments, technology disruptions and demand inflection points
Review Methodology & Data Structure
Preview report structure, data sources and research framework
Executive Summary
See What's Inside the Report
Get a preview of key findings, methodology and report coverage
Table of Contents
1. Executive Summary
2. Research Methodology
3. Ecosystem of Key Stakeholders in U.S. CRRT Market (Stakeholders, Roles, Interactions) [ICU & nephrology teams; perfusionists; dialysis providers; OEMs; consumables & fluid suppliers; catheter vendors; GPOs; distributors; payers (Medicare/Medicaid/commercial); FDA/CDC/AAMI/ISO; KOLs; EMR/tele-ICU vendors]
4. Value Chain Analysis (Inputs → OEM → Channel → Hospital → Service)
4.1 Delivery Model Analysis for CRRT-In-house ICU, Dialysis-provider supported, PIRRT/Hybrid, Vendor-managed service, Per-diem specialist (Margins, Preference, Strengths, Weaknesses)
4.2 Revenue Streams for U.S. CRRT Market (System, Consumables, Fluids, Services)
4.3 Business Model Canvas for U.S. CRRT (Key Partners, Activities, Resources, Value Props, Customer Segments, Channels, Cost, Revenue)
5. Market Structure (Channel, Contracting, Competition)
5.1 Per-Diem CRRT Specialists vs Employed ICU/Dialysis Staff (Capability, Cost, Coverage)
5.2 Investment Model in U.S. CRRT (CAPEX/OPEX Mix, Leasing, Bundles)
5.3 Procurement Funnel: Private vs Public/VA Hospitals (Stages, Criteria, Timelines)
5.4 CRRT Budget Allocation by Hospital Size, 2024 (Large/Academic vs Community)
6. Market Attractiveness for U.S. CRRT (Size, Growth, Profit Pools, Entry Barriers)
7. Supply-Demand Gap Analysis (Capacity, Staffing, Inventory, Seasonality)
8. Market Size for U.S. CRRT-Basis Revenues,
Historical revenues & volumes
9. Market Breakdown for U.S. CRRT-Basis (Historical)
9.1 By Market Structure (Hospital-Directed vs Outsourced Dialysis Support), 2023-2024P
9.2 By Modality (CVVH, CVVHD, CVVHDF, SCUF), 2023-2024P\
9.3 By Product Type (Systems, Consumables, Fluids, Catheters, Ancillaries), 2023-2024P
9.4 By End User (Academic Centers, Community Hospitals, Specialty ICUs, Pediatric/Neonatal Units), 2023-2024P
9.5 By Clinical Indication (Septic AKI, MOF, CRS, Hepatic AKI, Toxin), 2023-2024P
9.6 By Access Type (Dual-Lumen Catheter sites: IJ, Femoral, Subclavian), 2023-2024P
9.7 By Connectivity/IT (Standalone, EMR-Integrated, Tele-ICU Enabled), 2023-2024P
9.8 By Region (Northeast, Midwest, South, West; Urban vs Rural), 2023-2024P
10. Demand-Side Analysis for U.S. CRRT (Buyer Behavior, Cohorts, ROI)
10.1 Hospital Client Landscape & Cohort Analysis
10.2 Decision-Making Process
10.3 Training Effectiveness & ROI
10.4 Gap Analysis Framework
11. Industry Analysis
11.1 Trends & Developments (Automation, AI, Integrated Organ Support)
11.2 Growth Drivers (AKI incidence, ICU expansion, hemodynamic benefits)
11.3 SWOT Analysis (OEM & Market)
11.4 Issues & Challenges (Cost, training, reimbursement, supply)
11.5 Government & Regulatory Landscape (FDA pathways, CMS payment, AAMI/ISO)
12. Snapshot on Digital/Connected CRRT & Remote Support (Mini-Segment Deep-Dive)
12.1 Market Size & Future Potential, 2019-2030
12.2 Business Models & Revenue Streams
12.3 Delivery Models & Feature Sets
13. Opportunity Matrix-Radar Chart (Attractiveness vs Capability)
14. PEAK Matrix Analysis (Provider Capability x Market Impact)
15. Competitor Analysis for U.S. CRRT Market
15.1 Market Share of Key Players-Revenues, 2024
15.2 Benchmark of Key Competitors [Company overview; USP; strategy; business model; installed systems; revenues; pricing (system/consumables/fluids); technology (automation, connectivity); top filters/sets; major hospital clients; GPO ties; marketing; recent developments]
15.3 Operating Model Analysis Framework (Direct vs Distributor, GPO strategy, Service model)
15.4 Gartner-Style Positioning Matrix (Vision vs Execution for CRRT)
15.5 Bowman’s Strategic Clock (Price/Value positions by segment)
16. Future Market Size for U.S. CRRT-Basis Revenues, 2025-2030
Revenue & volume projections by driver stack
17. Market Breakdown for U.S. CRRT-Basis (Forecast)
17.1 By Market Structure (Hospital-Directed vs Outsourced Support), 2025-2030
17.2 By Modality (CVVH, CVVHD, CVVHDF, SCUF), 2025-2030
17.3 By Product Type (Systems, Consumables, Fluids, Catheters, Ancillaries), 2025-2030
17.4 By End User, 2025-2030
17.5 By Clinical Indication, 2025-2030
17.6 By Connectivity/IT, 2025-2030
17.7 By Region (Northeast, Midwest, South, West; Urban/Rural), 2025-2030
18. Recommendation
19. Opportunity Analysis
Discuss a Customized Research Scope
Custom research scope • Tailored insights • Industry expertise
Research Methodology
Step 1: Ecosystem Creation
We begin by mapping the ecosystem of the U.S. CRRT market, identifying both demand-side and supply-side entities. On the demand side, these include tertiary and community hospitals, trauma centers, pediatric ICUs, and integrated delivery networks (IDNs). On the supply side, entities include CRRT system manufacturers, filter and consumable producers, premixed fluid suppliers, catheter vendors, distributors, and GPOs (Group Purchasing Organizations). Based on this mapping, we shortlist 5–6 leading CRRT equipment and consumable providers in the U.S. such as Baxter, Fresenius, B. Braun, and Medtronic, using financial disclosures, client penetration in U.S. hospitals, and breadth of product portfolios. This stage leverages industry articles, FDA device approvals, CMS hospital databases, and proprietary secondary sources to collate robust ecosystem-level data.
Step 2: Desk Research
A structured desk research process is then undertaken, drawing insights from secondary and proprietary databases, FDA device registration repositories, CMS program statistics, and American Hospital Association datasets. We analyze CRRT revenues (systems, consumables, and fluids), hospital adoption patterns, number of ICU beds, filter usage rates, and modality adoption (CVVH, CVVHD, CVVHDF, SCUF). Company-level data from annual reports, investor presentations, regulatory filings, and press releases are also evaluated. This enables us to map pricing ladders for filters and fluids, capital system procurement patterns, consumables attach rates, and reimbursement-related variables. The goal of this step is to develop a comprehensive foundation of market insights before validation.
Step 3: Primary Research
We conduct in-depth interviews with CRRT stakeholders, including ICU directors, nephrologists, critical-care nurses, supply chain managers, and C-level executives from device OEMs and distributors. These interviews serve to validate hypotheses around filter life, system uptime, adoption of anticoagulation protocols, and pricing/contracting models. A bottom-up approach is employed to estimate hospital-level spend on CRRT systems and consumables, aggregating to market-level revenues. As part of validation, disguised interviews are conducted by approaching companies as prospective clients, which provides candid insights on service agreements, revenue streams, procurement hurdles, and training costs. This dual method ensures that our operational and financial insights align with real-world market functioning.
Step 4: Sanity Check
Finally, a top-to-bottom and bottom-to-top triangulation is executed to validate the overall market sizing. This includes reconciling hospital admission volumes with estimated CRRT penetration rates, consumable throughput per procedure, and fluid replacement volumes. The outcomes are cross-checked against ICU bed counts, sepsis hospitalization data, and FDA-approved installed base figures to ensure coherence. Sensitivity analyses are also applied to account for regional variation in adoption (e.g., higher usage in Northeast academic centers versus smaller Midwest community hospitals). This stage ensures the accuracy and reliability of final market models before report release.
See What's Inside the Report
Get a preview of key findings, methodology and report coverage
Frequently Asked Questions
01 What is the Potential for the U.S. Continuous Renal Replacement Therapy (CRRT) Market?
The U.S. Continuous Renal Replacement Therapy market holds significant potential, reaching a valuation of USD 408.1 million in 2023. Its expansion is driven by rising ICU admissions linked to acute kidney injury (AKI), sepsis-related multi-organ dysfunction, and the increasing availability of FDA-cleared CRRT systems and consumables. With 6,093 hospitals and nearly 788,000 staffed beds supporting critical-care throughput, the market’s potential is reinforced by strong clinical preference for CRRT in hemodynamically unstable patients and the steady adoption of automated, connected CRRT platforms.
02 Who are the Key Players in the U.S. Continuous Renal Replacement Therapy (CRRT) Market?
The U.S. CRRT market features several key players, including Baxter International, Fresenius Medical Care, and B. Braun Melsungen AG, who dominate through extensive system installations, consumables portfolios, and nationwide service networks. Other notable players include Nikkiso, Asahi Kasei Medical, Toray Medical, Nipro, Medtronic (Carpediem pediatric CRRT), BD, Teleflex, Medcomp, Infomed SA, Outset Medical, Quanta Dialysis Technologies, and Fresenius Kabi. These companies maintain market strength through FDA-cleared technologies, strong GPO contracts, and robust hospital partnerships.
03 What are the Growth Drivers for the U.S. Continuous Renal Replacement Therapy (CRRT) Market?
Key growth drivers include the 1.7 million annual sepsis hospitalizations in the U.S., which directly feed demand for CRRT in critically ill patients. Additionally, the country’s large healthcare infrastructure, with 34 million hospital admissions annually, provides the throughput that sustains continuous demand for filters, fluids, and systems. Regulatory clarity from FDA, coupled with technological advances such as EMR integration and smart fluid management, further supports adoption. Together, these factors establish a strong base for sustained growth of CRRT adoption across U.S. hospitals.
04 What are the Challenges in the U.S. Continuous Renal Replacement Therapy (CRRT) Market?
The U.S. CRRT market faces several challenges. Staffing shortages are acute, with the Bureau of Labor Statistics projecting 189,100 RN openings annually, straining ICU capacity to manage 24×7 CRRT protocols. Supply chain risks around filters, fluids, and catheters also create bottlenecks, especially during hospital surges. Additionally, high consumables usage rates raise budget pressures in community hospitals, where value analysis committees scrutinize costs against patient outcomes. These constraints, coupled with the complexity of anticoagulation management and circuit downtime, present notable hurdles for sustained CRRT adoption.
License Options
PDF + Excel
Complete report package
$4,000
Excel Only
Data and analytics
$2,500